UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Negative Ion Tandem Mass Spectrometry for the Detection of Glutathione Conjugates

Chemical research in toxicology, 2005-04, Vol.18 (4), p.630-638

2005

Volltextzugriff (PDF)

Collection of selected reaction monitoring and full scan data on a time scale suitable for target compound quantitative analysis by liquid chromatography/tandem mass spectrometry

Rapid communications in mass spectrometry, 2003-01, Vol.17 (21), p.2413-2422

2003

Volltextzugriff (PDF)

The emergence and application of technological advances in biotransformation studies

Current topics in medicinal chemistry, 2002-01, Vol.2 (1), p.67

2002

Volltextzugriff (PDF)

Application of Technological Advances in Biotransformation Studies

Integrated Strategies for Drug Discovery Using Mass Spectrometry, 2005, p.261-287

2005

Volltextzugriff (PDF)

Rapid liquid chromatography with tandem mass spectrometry-based screening procedures for studies on the biotransformation of drug candidates

Drug metabolism and disposition, 1999-01, Vol.27 (1), p.32

1999

Volltextzugriff (PDF)

Non-peptide alpha(v)beta(3) antagonists: identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint

Bioorganic & medicinal chemistry letters, 2003-12, Vol.13 (24), p.4285-4288

2003

Volltextzugriff (PDF)

Non-Peptide α vβ 3 antagonists. Part 3: Identification of potent RGD mimetics incorporating novel β-Amino acids as aspartic acid replacements

Bioorganic & medicinal chemistry letters, 2002-01, Vol.12 (1), p.31-34

2002

Volltextzugriff (PDF)

Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies

Drug metabolism and disposition, 1996-11, Vol.24 (11), p.1263

1996

Volltextzugriff (PDF)

Nonpeptide αvβ3 Antagonists. 8. In Vitro and in Vivo Evaluation of a Potent αvβ3 Antagonist for the Prevention and Treatment of Osteoporosis

Journal of medicinal chemistry, 2003-10, Vol.46 (22), p.4790-4798

2003

Volltextzugriff (PDF)

Kinesin spindle protein (KSP) inhibitors. Part 6: Design and synthesis of 3,5-diaryl-4,5-dihydropyrazole amides as potent inhibitors of the mitotic kinesin KSP

Bioorganic & medicinal chemistry letters, 2007-10, Vol.17 (19), p.5390-5395

2007

Volltextzugriff (PDF)

Kinesin spindle protein KSP inhibitors. Part 8: Design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP

Bioorganic & medicinal chemistry letters, 2007, Vol.17 (20), p.5677-5682

2007

Volltextzugriff (PDF)

Non-peptide αvβ3 antagonists: Identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint

Bioorganic & medicinal chemistry letters, 2003-12, Vol.13 (24), p.4285-4288

2003

Volltextzugriff (PDF)

Non-peptide αvβ3 antagonists. Part 3: Identification of potent RGD mimetics incorporating novel β-amino acids as aspartic acid replacements

Bioorganic & medicinal chemistry letters, 2002-01, Vol.12 (1), p.31-34

2002

Volltextzugriff (PDF)

Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis

Journal of medicinal chemistry, 2003-10, Vol.46 (22), p.4790-4798

2003

Volltextzugriff (PDF)

Nonpeptide α v β 3 Antagonists. 8. In Vitro and in Vivo Evaluation of a Potent α v β 3 Antagonist for the Prevention and Treatment of Osteoporosis

Journal of medicinal chemistry, 2003-10, Vol.46 (22), p.4790-4798

2003

Volltextzugriff (PDF)

Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements

Bioorganic & medicinal chemistry letters, 2002-01, Vol.12 (1), p.31

2002

Volltextzugriff (PDF)

1 – 17 von 17

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(16)
Buchkapitel
(1)

Sprache

Englisch
(17)

Erscheinungsjahr

n.n

Zeitschrift / Serie

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Negative Ion Tandem Mass Spectrometry for the Detection of Glutathione Conjugates

Collection of selected reaction monitoring and full scan data on a time scale suitable for target compound quantitative analysis by liquid chromatography/tandem mass spectrometry

The emergence and application of technological advances in biotransformation studies

Application of Technological Advances in Biotransformation Studies

Rapid liquid chromatography with tandem mass spectrometry-based screening procedures for studies on the biotransformation of drug candidates

Non-peptide alpha(v)beta(3) antagonists: identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint

Non-Peptide α vβ 3 antagonists. Part 3: Identification of potent RGD mimetics incorporating novel β-Amino acids as aspartic acid replacements

Kinesin Spindle Protein (KSP) Inhibitors. 9. Discovery of (2S)-4-(2,5-Difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the Treatment of Taxane-Refractory Cancer

Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies

Nonpeptide αvβ3 Antagonists. 8. In Vitro and in Vivo Evaluation of a Potent αvβ3 Antagonist for the Prevention and Treatment of Osteoporosis

Kinesin spindle protein (KSP) inhibitors. Part 6: Design and synthesis of 3,5-diaryl-4,5-dihydropyrazole amides as potent inhibitors of the mitotic kinesin KSP

Kinesin spindle protein KSP inhibitors. Part 8: Design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP

Non-peptide αvβ3 antagonists: Identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint

Non-peptide αvβ3 antagonists. Part 3: Identification of potent RGD mimetics incorporating novel β-amino acids as aspartic acid replacements

Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis

Nonpeptide α v β 3 Antagonists. 8. In Vitro and in Vivo Evaluation of a Potent α v β 3 Antagonist for the Prevention and Treatment of Osteoporosis

Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements

Suchergebnisse filtern